Kerri Fitzgerald

DocwireNews

Here are the top stories covered by DocWire Newsthis week in the Hematology &amp; Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved multiple drugs and issued several warnings, a study found that certain e-Cigarette flavors contain a cancer-causing compound, and more.According to a study published in&nbsp;JAMA Internal Medicine, <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/mint-and-menthol-flavored-e-cigarette-liquids-contain-cancer-causing-compound/">potentially&nbsp;high levels of a cancer-causing compound&nbsp;have been found in mint and menthol flavored e-cigarette</a>liquids and smokeless tobacco products.Between 2010 and 2013, nearly 100 U.S. women&rsquo;s health clinics closed due to state restrictions placed on reproductive services.&nbsp;Because of this, researchers have observed <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/closure-of-womens-health-clinics-resulting-in-increased-cases-of-cervical-cancer/">adverse effects on women&rsquo;s health</a>, including&nbsp;decreased screening, increased stage at presentation, and higher mortality from cervical cancer, according to data presented at the 2019 ASTRO Annual Meeting and published in the&nbsp;International Journal of Radiation Oncology.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-expands-approval-for-erleada-in-prostate-cancer/">The FDA expanded the approval of Erleada&reg;</a>(apalutamide) to include the treatment of men with&nbsp;metastatic castration-sensitive prostate cancer. The oral androgen receptor inhibitor was previously approved to treat non-metastatic castration-resistant prostate cancer.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-endocrine-cancer-treatment-under-new-international-network-pathway/">The FDA granted accelerated approval to Lenvima&reg;</a>(lenvatinib) plus Keytruda&reg; (pembrolizumab) for the treatment advanced&nbsp;endometrial carcinoma&nbsp;that is not microsatellite instability-high or mismatch repair deficient in patients whose disease has progressed following prior systemic therapy but are not candidates for curative surgery or radiation.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-says-some-heartburn-drugs-may-be-linked-to-cancer/">The FDA warned that some heartburn drugs</a>, including Zantac&reg; (ranitidine), contain low levels of N-nitrosodimethylamine, a nitrosamine impurity&nbsp;that is classified as a probable human carcinogen that could cause cancer.In case you missed it, more hem/onc headlines are featured below:<ul>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-warns-that-several-breast-cancer-drugs-lead-to-lung-inflammation/">FDA Warns That Several Breast Cancer Drugs Lead to Lung Inflammation</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/erleada-vs-xtandi-a-comparison-of-prostate-cancer-drugs/">Erleada vs. Xtandi: A Comparison of Prostate Cancer Drugs</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/americans-unaware-hpv/">Most Americans Are Unaware that HPV Causes Cancer</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/googles-ai-detects-26-skin-diseases-with-accuracy-comparable-to-dermatologists/">Google&rsquo;s AI Detects 26 Skin Diseases with Accuracy Comparable to Dermatologists</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/study-supports-use-of-psoriasis-drugs-in-treating-bone-cancer/">Study Supports Use of Psoriasis Drugs in Treating Bone Cancer</a></li>
</ul>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Hem/Onc Roundup: This e-Cigarette Flavor Is Linked to Cancer, FDA Approvals/Warnings, and more

Oncology

Here are the top stories covered by DocWire Newsthis week in the Hematology &amp; Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved multiple ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe